Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Quantitative proteomic analysis shows differentially expressed HSPB1 in glioblastoma as a discriminating short from long survival factor and NOVA1 as a differentiation factor between low-grade astrocytoma and oligodendroglioma

Fig. 3

Validation of proteomic data of HSPB1 in glioma patient samples. a qRT-PCR of HSPB1 gene in GBM patient samples with short survival time (<12 months) and long survival (>16 months). b Re-analysis of the qRT-PCR of HSPB1 gene in samples for a longer interval between short (<12 months) and long survival patients (>24 months). Data analyses were normalized by the same set of housekeeping genes: HPRT, GUSB, TBP and Mann Whitney statistical test. c Western blot of HSPB1 in individual astrocytoma patient samples (n = 3 and 4); (NN = non-neoplastic tissue; AST II = astrocytoma grade II, GBM-SS = glioblastoma short survival and GBM-LS = glioblastoma long survival. d Immunohistochemistry (IHC) of HSPB1 in low-grade to high-grade gliomas. a Non neoplastic (NN); b Pilocytic astrocytoma (ASTI); c Diffuse astrocytoma (ASTII); d Anaplastic astrocytoma (ASTIII), and e Glioblastoma (GBM) short survival (5 months), and f GBM long survival (27 months). g graphical-plot of IHC relative expression of HSPB1

Back to article page